Adaptive Biotechnologies (ADPT) Other financing activities (2018 - 2026)

Adaptive Biotechnologies has reported Other financing activities for 9 years, with the latest figure at $5.0 million in Q1 2026.

• Quarterly Other financing activities fell 7.82% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (up 123.75% YoY) and the FY2025 annual result came in at $12.5 million, changed N/A from the prior year.
• Other financing activities climbed to $5.0 million in Q1 2026 per ADPT's latest filing, from $3.8 million in the prior quarter.
• Over five years, Other financing activities peaked at $116.8 million in Q4 2022 and troughed at -$2.2 million in Q4 2023.
• A 5-year average of $8.3 million and a median of $1.5 million in 2023 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2025: Other financing activities sank 101.85% in 2023, then soared 12288.64% in 2025.
• Over 5 years, Other financing activities stood at $116.8 million in 2022, then sank by 101.85% to -$2.2 million in 2023, then surged by 94.72% to -$114000.0 in 2024, then soared by 3414.91% to $3.8 million in 2025, then surged by 32.97% to $5.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $5.0 million, $3.8 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.